Press release
Obesity Market Size was USD 1,052 Million in 2021
Key takeaways from the Obesity Market Research Report
• Total prevalent cases of obesity in adults (>19 years) were 182.22 Million (M) and in children (5-19 years) were 7.85 million in the 7MM which are expected to grow during the study period, i.e., 2019-2032.
• In 2021, the total Obesity market size was USD 1,052 million which is expected to rise during the study period (2019-2032).
• Obesity Market Companies are working such as Novo Nordisk, Eli Lilly and Company, MedImmune, Boehringer Ingelheim, Raziel Therapeutics, Altimmune, Saniona, YSOPIA Bioscience, Innovent Biologics, Glaceum, Shionogi, Aardvark Therapeutics, NuSirt Biopharma, Novartis, CSPC Baike (Shandong) Biopharmaceutical, Jiangsu HengRui Medicine, Carmot Therapeutics, Pfizer, Sciwind Biosciences, Empros Pharma and others.
• Obesity Pipeline therapies include VI-0521, THR-4109, topiramate, phentermine, PF-06882961, Rosuvastatin, Midazolam, Tesofensine and others.
To read more about the latest drug development related to Obesity, get a snapshot of the key highlights included in the Obesity Market Outlook @ https://www.delveinsight.com/report-store/weight-loss-weight-management-obesity-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Obesity Overview
Obesity is a complicated condition characterized by an excess of body fat. Obesity is more than simply an aesthetic issue. It is a medical condition that raises the risk of developing other diseases and health issues, such as heart disease, diabetes, high blood pressure, and some malignancies. Some people struggle to lose weight for a variety of reasons. Obesity is typically caused by a combination of genetic, physiological, and environmental variables, as well as dietary, physical activity, and exercise decisions.
Obesity Epidemiology Segmentation in the 7MM
• Total Obesity Prevalent Cases
• Total Obesity Patients Seeking Help
• Total Obesity Treated Cases
To know more about the Obesity drugs market growth, get a snapshot of the report Obesity Market Analysis Report @ https://www.delveinsight.com/report-store/weight-loss-weight-management-obesity-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Obesity Treatment Market
Losing weight through healthy eating, increasing physical activity, and making other lifestyle changes are all common therapies for obesity. Some people may benefit from weight-management programs in order to lose weight or avoid regaining it. Some obese persons are either unable to drop enough weight to enhance their health or are unable to maintain their weight loss. Other therapies, such as weight-loss drugs, gadgets, or bariatric surgery, may be considered in such circumstances.
Within the first 6 months of treatment, it is recommended to decrease 5-10% of the body weight. It can help reduce the risk of developing obesity-related health problems, and improve health conditions associated with obesity, such as high blood pressure and high cholesterol levels. So obesity can be managed by reducing calories and adopting healthier eating habits, physical activity, and weight loss medications like orlistat and phentermine.
Obesity Companies and Pipeline Therapies
• Novo Nordisk: VI-0521
• Eli Lilly and Company: THR-4109
• MedImmune: topiramate
• Boehringer Ingelheim: phentermine
• Raziel Therapeutics: PF-06882961
• Altimmune: Rosuvastatin
• Saniona: Midazolam
• YSOPIA Bioscience: Tesofensine
Get a sneak peek at the Obesity Market Dynamics @ https://www.delveinsight.com/sample-request/weight-loss-weight-management-obesity-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Obesity Market Report
• Coverage- 7MM
• Study Period- 2019-2032
• Forecast Period- 2022-2032
• Obesity Companies- Novo Nordisk, Eli Lilly and Company, MedImmune, Boehringer Ingelheim, Raziel Therapeutics, Altimmune, Saniona, YSOPIA Bioscience, Innovent Biologics, Glaceum, Shionogi, Aardvark Therapeutics, NuSirt Biopharma, Novartis, CSPC Baike (Shandong) Biopharmaceutical, Jiangsu HengRui Medicine, Carmot Therapeutics, Pfizer, Sciwind Biosciences, Empros Pharma and others
• Obesity Pipeline therapies- VI-0521, THR-4109, topiramate, phentermine, PF-06882961, Rosuvastatin, Midazolam, Tesofensine and others
• Obesity Market Drivers and Barriers, Unmet Needs
Read more about the Obesity treatment market report @ https://www.delveinsight.com/sample-request/weight-loss-weight-management-obesity-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Key Insights
2. Obesity Report Introduction
3. Obesity Market Overview at a Glance
4. Key Events
5. Epidemiology and Market Methodology
6. Disease Background and Overview
7. Obesity Diagnosis
8. Treatment and Management
9. Epidemiology and Patient Population
10. Obesity: Country-wise Epidemiology
11. Patient Journey
12. Obesity Marketed Therapies
13. Emerging Obesity Therapies
14. Conjoint Analysis
15. Obesity: 7 Major Market Analysis
16. Reimbursement and Market access
17. KOL Views
18. Obesity Market Drivers
19. Obesity Market Barriers
20. SWOT Analysis
21. Unmet Needs
22. Appendix
23. DelveInsight Capabilities
24. Disclaimer
25. About DelveInsight
Learn more about the Obesity Market Drivers and Barriers @ https://www.delveinsight.com/sample-request/weight-loss-weight-management-obesity-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 09193216187
Address: 304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Obesity Market Size was USD 1,052 Million in 2021 here
News-ID: 2834201 • Views: …
More Releases from DelveInsight Business Research
Amyotrophic Lateral Sclerosis Market Forecast 2034: FDA, EMA, PDMA Approvals, Cl …
Amyotrophic Lateral Sclerosis companies are Biogen, Ionis Pharmaceuticals, Ferrer Internacional S.A., AbbVie, Calico Life Sciences LLC, Genuv Inc., Kadimastem, Corcept Therapeutics, AL-S Pharma, Rapa Therapeutics LLC, Cytokinetics, MediciNova, Retrotope, Inc. Woolsey Pharmaceuticals, Sanofi, PTC Therapeutics, Helixmith Co., Ltd., Annexon, Inc., Denali Therapeutics Inc., Revalesio Corporation, Clene Nanomedicine, Ashvattha Therapeutics, Inc., Apellis Pharmaceuticals, Inc., Procypra Therapeutics, Knopp Biosciences, InFlectis BioScience, AI Therapeutics, Inc., Cellenkos, ZZ Biotech, LLC, QurAlis Corporation, Alector Inc.,…
PD1 and PDL1 Inhibitors Market Forecast 2034: FDA, EMA, PDMA Approvals, Clinical …
(Albany, USA) DelveInsight's PD1 and PDL1 Inhibitors Competitive Landscape report delivers an in-depth understanding of the PD1 and PDL1 inhibitors and the PD1 and PDL1 inhibitors market trends in the 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].
Request for sample report to know more about the PD1 and PDL1 Inhibitors market report offerings @ https://www.delveinsight.com/report-store/pd-1-pdl-1-inhibitors-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Key Takeaways from the PD1 and PDL1 Inhibitors…
Heart Failure Pipeline and Clinical Trials Assessment 2024: FDA Approvals, Thera …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Heart Failure pipeline constitutes 75+ key companies continuously working towards developing 90+ Heart Failure treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Heart Failure Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Heart Failure Market.
The Heart…
Primary Hyperoxaluria Pipeline and Clinical Trials Assessment: FDA Approvals, Th …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Primary Hyperoxaluria pipeline constitutes 8+ key companies continuously working towards developing 8+ Primary Hyperoxaluria treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Primary Hyperoxaluria Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Primary Hyperoxaluria Market.
The Primary…
More Releases for Obesity
Anti-Obesity Drugs (Anti-obesity Medication) Market Will Generate Massive Revenu …
Latest survey on Anti-Obesity Drugs (Anti-obesity Medication) Market is conducted to provide hidden gems performance analysis of Anti-Obesity Drugs (Anti-obesity Medication) to better demonstrate competitive environment . The study is a mix of quantitative market stats and qualitative analytical information to uncover market size revenue breakdown by key business segments and end use applications. The report bridges the historical data from 2017 to 2022 and forecasted till 2027*, the outbreak…
Increasing Prevalence of Obesity Driving Obesity/Bariatric Surgery Devices Marke …
The global obesity/bariatric surgery devices market revenue stood at $1.4 billion in 2016, and it is expected to rise to $2.8 billion by 2023. Furthermore, the market will progress at a CAGR of 9.9% from 2017 to 2023 (forecast period), as per the estimates of the market research company, P&S Intelligence. The major growth drivers of the market are the rising incidence of obesity, owing to unhealthy diets and lifestyle…
Covid-19 pandemic fuels pet obesity.
Covid-19 pandemic fuels pet obesity.
Fit4dogsuk, is currently helping dog owners in the East Yorkshire area during the Pandemic, with the weight loss challenge for their canine companions.
As we have all been forced to change our habits during Covid 19, this has also had an effect on our dog’s. Their eating habits, activity levels and weight, have all changed and this can quickly affect their quality of life. A…
Fast Food and Obesity
Most of the fast food in the market contains a large quantity of sugar, #carbs and fats with a lesser quantity of vitamins and minerals. The unhealthy food ingredients in the fast food are further increased with increased portion size. The person will still consume the whole meal regardless of being completely full. People cannot stop ravishing on fast food because it is available for low cost and in close…
Obesity Management Congress 2018
Obesity can be managed by combination of lifestyle change, exercise and healthy diet plans. In case of severe Obesity bariatric surgery and medications will be employed. People who have gone through bariatric surgery which have suppressed hunger and the mechanism for which causes obesity based type 2 diabetes is reversed and it also causes sixty to eighty percent weight loss for a long term. But it has it cons…
Obesity Treatment Market driven by rise in childhood obesity rates
Obesity is a disorder in which excess body fat gets accumulated to such extent that it may have negative effects on health. It occurs over time when people eat more calories than they utilize. The reasons for obesity can be medical problems, inactivity, genetics, family lifestyle, unhealthy diet, medications, age, and pregnancy. Being obese increases the risk of diabetes, heart disease, stroke, arthritis, and some type of cancers.
Obesity treatment…
